ACHN Volume Alert - ACHN 12.18 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 11:37 AM

ACHN Volume Alert - ACHN 12.18 Achillion Pharmaceuticals $ACHN Hit a high of 12.75 Currently 11:15 Last price 12.18 +2.07 +20.47% With a day low of 10.67 and a current volume of 12,258,331.

ACHN Achillion Pharmaceuticals Recent Headline News

Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 22 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.33 (+0.13), GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30), BMY: 58.54 (+0.22)

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 56 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11), RGLS: 24.03 (+1.95), ABBV: 63.80 (+2.30)

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.22 (+2.11)

Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.22 (+2.11)

Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 108.11 (+1.66), ACHN: 12.22 (+2.11)

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (unch), HSKA: 15.87 (-0.03), ACHN: 12.22 (+2.11), AMAG: 34.83 (-0.12)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.06 (+0.06), ALIM: 5.03 (-0.03), ACHN: 12.22 (+2.11), FNHC: 26.80 (+0.66), ARCP: 8.63 (-0.16), CKEC: 28.29 (+0.39), JAXB: 12.01 (+0.32), PCLN: 1,104.96 (+10.35), TESO: 16.00 (-0.06)

Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.08 (-0.52), PLUG: 5.40 (+0.10), NYMX: 0.72 (-0.03), INTC: 33.38 (-0.20), FOX: 33.22 (-0.02), SAPE: 24.67 (unch), GERN: 2.26 (-0.07), ACHN: 12.22 (+2.11), FOXA: 34.66 (+0.05), ODP: 6.51 (+0.01), ARCP: 8.63 (-0.16), MSFT: 48.92 (+0.24), GRPN: 7.58 (+0.08), AAPL: 109.17 (+0.16)

Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.22 (+2.11)

Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.43 (+3.59), CYTX: 0.41 (-0.02), ACHN: 12.22 (+2.11), INCY: 70.30 (+0.98), SRPT: 16.48 (+0.36)

Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 12.22 (+2.11)

Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 12.22 (+2.11)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.11 (+1.66), CLVS: 58.63 (+0.32), ARWR: 6.35 (+0.29), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), RTRX: 10.33 (-0.05), RGLS: 24.03 (+1.95), EPZM: 23.74 (-0.01), AGIO: 77.16 (+5.10), RMTI: 10.26 (-0.29), ARNA: 4.31 (+0.05), KERX: 16.49 (-0.24)

Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 388.33 (+4.17), ACHN: 12.22 (+2.11), CVS: 88.72 (+0.34), N: 109.92 (+0.84), PAY: 37.15 (+0.59)

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 108.09 (+1.64), ACHN: 12.22 (+2.11), MRK: 58.35 (-0.99), ABBV: 63.80 (+2.30)

Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.28 (-0.59), FBHS: 43.07 (+0.27), ACHN: 12.22 (+2.11), KBH: 16.67 (+0.33), HOV: 4.02 (+0.25)

November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 12.22 (+2.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blue Moon Metals Gears Up for Springer Mine Revamp

Getting Set for a Big Move Blue Moon Metals Inc. isn't sitting around with its thumbs in its pockets. The company has made some strides with their Springer Tungsten Mine project in Imlay, Nevada. Let's break down what these folks are up to. Refurbished Up for the Fast Track The rock mover here is the refurbishment of the Springer processing plant. You don't just snap your...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Netcapital's 28.62% Plunge: A Fraudulent Drama Unfolds

Netcapital: The Plunge Heard 'Round the Market There it is, clear as day—Netcapital’s (NASDAQ: NCPL) stock plummeting 28.62% like a lead balloon. Shareholders had to watch in horror as pieces of their investments seemed to evaporate, all thanks to a swirl of alleged fraud. You can't just shrug off accusations that a company you've betted on has been cooking its books,...

Boscia's Future Ties Tradition and Modern Science

Reviving a Skincare Legacy With the wind of innovation at its back, The Center Brands and Dr. Mamina Turegano are stepping in to breathe new life into Boscia. Now, I'm not just talking about a simple facelift. We're talking about an all-out integration of traditional Japanese skincare principles with the sharp edge of modern dermatologic science. It's a brave move...

University of Phoenix Grads Gain High Praise from Managers

Forget the stereotypes that tag University of Phoenix as just another factory for diplomas. The latest survey results paint a picture of graduates who seem to be real go-getters in the workplace. We’ve got managers from all over singing the praises of these alums, with a whopping 96% ready to vouch for them stepping into bigger roles. Not just talk, folks, this is their...

Elbit Systems Lands $200M APAC ISTAR Contracts

By Ryan Hughes Updated Oct 26, 2026 Category News Views 100

Elbit Systems Secures Major Asia-Pacific Deal You know, it's not every day that a defense contractor like Elbit Systems (NASDAQ:ESLT) bags a $200 million deal in the Asia-Pacific region. A big move in a high-stakes game where technology, strategy, and geography collide. This isn't some random supply deal; this involves the cutting edge of defense tech—ISTAR and training...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Gentex Faces Investigation as Shares Tumble 7%

Investigating Gentex's Financial Setback Gentex Corporation, ticker NASDAQ:GNTX, is caught in a bit of a blizzard right now. Their shares took a nosedive, down 7%, after some messy numbers came out in their third-quarter report—tariffs and the kind of pricing pressure that makes grown investors wince. If you threw your chips in on Gentex and got burned, the lawyers are...

MacDonald Steps Up as President at California Bank

New Leadership at California Bank & Trust It's a big shakeup in the banking lanes today as Michael MacDonald grabs the helm at California Bank & Trust (CB&T). He's stepping into the President's shoes, bringing along a toolkit of experience and know-how that's tough to find elsewhere. Under his watch, CB&T aims to blend the nimble maneuvering of local banks with the clout...